Stocks › ABT
ABBOTT LABORATORIES
ABT·NYSE·
United States·USD
$103.00
-0.87 (-0.84%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ABT
ABBOTT LABORATORIES · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ABTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ABT by members of U.S. Congress · 402 on record · 54 in the last 12 months
Whale Activity
Position changes in ABT reported for 2026-09-30 by 3164 institutional filers
- Increased1202
- New211
- Held383
- Decreased1130
- Closed118
- No prior filing120
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 151.7M | $14.99B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 113.3M | $11.19B | decreased |
| STATE STREET CORP | 81.4M | $8.05B | increased |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 57.2M | $5.65B | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 47.9M | $4.74B | decreased |
| Capital Research Global Investors | 45.0M | $4.45B | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 39.6M | $3.89B | increased |
| Capital International Investors | 35.5M | $3.51B | increased |
| JPMORGAN CHASE & CO | 29.7M | $3.00B | increased |
| MORGAN STANLEY | 28.9M | $2.86B | increased |
| FRANKLIN TEMPLETON INC | 20.4M | $2.36B | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 23.5M | $2.33B | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ABT insiders, by quarter · Form 4
Recent Insider Transactions
6,440 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Moreland Mary KEXECUTIVE VICE PRESIDENT | Sale | −3,500 | $116.00 | $406K | Nov 5, 2026 | Form 4 ↗ |
| Conroy Kevin TDirector | Tax withholding | −52.5K | $103.99 | $5.5M | Sep 23, 2026 | Form 4 ↗ |
| MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER | Sale | −27 | $109.54 | $3K | Sep 2, 2026 | Form 4 ↗ |
| Boudreau Philip PEVP AND CFO | Tax withholding | −388 | $110.36 | $43K | Sep 1, 2026 | Form 4 ↗ |
| MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER | Tax withholding | −52 | $110.36 | $6K | Sep 1, 2026 | Form 4 ↗ |
| Ford Robert BCHAIRMAN AND CEO · Director | Sale | −180.3K | $116.19 | $20.9M | Aug 25, 2026 | Form 4 ↗ |
| Ford Robert BCHAIRMAN AND CEO · Director | Sale | −218.5K | $115.57 | $25.3M | Aug 25, 2026 | Form 4 ↗ |
| Ford Robert BCHAIRMAN AND CEO · Director | Option exercise | +247.0K | $59.94 | $14.8M | Aug 25, 2026 | Form 4 ↗ |
| Ford Robert BCHAIRMAN AND CEO · Director | Option exercise | +151.9K | $44.40 | $6.7M | Aug 25, 2026 | Form 4 ↗ |
| Morrone Louis H.EXECUTIVE VICE PRESIDENT | Discretionary | −12 | $107.99 | $1K | Aug 12, 2026 | Form 4 ↗ |
| Morrone Louis H.EXECUTIVE VICE PRESIDENT | Sale | −5,850 | $109.83 | $643K | Aug 11, 2026 | Form 4 ↗ |
| Morrone Louis H.EXECUTIVE VICE PRESIDENT | Tax withholding | −269 | $92.71 | $25K | Jun 30, 2026 | Form 4 ↗ |
| Cushman Elizabeth C.EVP, GC AND SECRETARY | Tax withholding | −560 | $94.12 | $53K | Jun 27, 2026 | Form 4 ↗ |
| Stratton John GDirector | Purchase | +2,000 | $86.82 | $174K | May 7, 2026 | Form 4 ↗ |
| Moreland Mary KEXECUTIVE VICE PRESIDENT | Discretionary | +5,314 | $94.41 | $502K | Apr 28, 2026 | Form 4 ↗ |
| STARKS DANIEL JDirector | Purchase | +10.0K | $92.65 | $927K | Apr 27, 2026 | Form 4 ↗ |
| Ahuja NitaDirector | Grant / award | +2,286 | $0.00 | $0 | Apr 24, 2026 | Form 4 ↗ |
| Gonzalez Patricia PaolaDirector | Grant / award | +2,286 | $0.00 | $0 | Apr 24, 2026 | Form 4 ↗ |
| McDew Darren WDirector | Grant / award | +2,286 | $0.00 | $0 | Apr 24, 2026 | Form 4 ↗ |
| Babineaux-Fontenot ClaireDirector | Grant / award | +2,286 | $0.00 | $0 | Apr 24, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ABT · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Schwab U.S. Dividend Equity ETF SCHWAB STRATEGIC TRUST | 47.6M | $5.26B | 4.68% | Aug 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 55.3M | $5.02B | 0.22% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 45.1M | $4.10B | 0.25% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 22.6M | $2.50B | 0.29% | Aug 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 24.0M | $2.17B | 0.24% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 21.1M | $1.92B | 0.25% | Jun 30, 2026 |
| Washington Mutual Investors Fund | 17.5M | $1.85B | 0.85% | Jul 31, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 16.6M | $1.50B | 0.59% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF SELECT SECTOR SPDR TRUST | 12.3M | $1.12B | 2.75% | Jun 30, 2026 |
| VANGUARD DIVIDEND APPRECIATION INDEX FUND VANGUARD SPECIALIZED FUNDS | 9.9M | $1.04B | 0.80% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ABT's shares (CUSIP 002824100), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming abbott laboratories as client
- PHRONESISDC, LLCABBOTT LABORATORIES · 2026 Q3 · TAX, RET$50K
Filing ↗ - DUDDINGTON GLOBAL STRATEGIES LLCABBOTT LABORATORIES · 2026 Q3 · VET$10K
Filing ↗ - MARSHALL & POPP, LLCABBOTT LABORATORIES · 2026 Q3 · TAX, DEF, HCR, TRD$60K
Filing ↗ - THE DUBERSTEIN GROUP INC.ABBOTT LABORATORIES · 2026 Q3—
Filing ↗ - ABBOTT LABORATORIESABBOTT LABORATORIES · 2026 Q3 · HCR, MMM, TRD, LAW$1.3M
Filing ↗
Government Contracts
Federal awards to abbott laboratories · USAspending
$261.3MAwarded · 452 contracts on record
- Department of StateMEDICAL SUPPLIES$21K
Sep 29, 2026 · ↗ - Department of StateMEDICAL SUPPLIES$21K
Sep 14, 2026 · ↗ - Department of Health and Human ServicesEO 14398 ALINITY MAINTENANCE AND SUPPLIES$325K
Jun 26, 2026 · ↗ - Department of Veterans AffairsABBOTT ENSITE AND CLARIS ANNUAL PM SERVICES BASE YEAR$86K
Mar 14, 2025 · ↗ - Department of Veterans AffairsARCHITECT REAGENT ORDER$95K
Jul 1, 2025 · ↗ - Department of Veterans AffairsISTAT POINT OF CARE SYSTEM$3.1M
Mar 15, 2022 · ↗ - Department of Veterans AffairsREGENTS$249K
Oct 1, 2024 · ↗ - Department of Veterans AffairsNTX IMMUNOASSAY CPT - ORDER 1$309K
Jul 1, 2025 · ↗
U.S. Patents
Recent USPTO applications naming ABBOTT LABORATORIES
No USPTO patent applications found for ABBOTT LABORATORIES.
Annual Financials
From ABT's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B |
| Diluted EPS | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B |
| Cash and equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B |
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B |
| Shareholders' equity | $52.13B | $47.66B | $38.60B | $36.69B | $35.80B |
As ABBOTT LABORATORIES tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 20, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 31-for-29Stock splitMay 3, 2004
- 2-for-1Stock splitJun 1, 1998
- 2-for-1Stock splitJun 1, 1992
- 2-for-1Stock splitJun 1, 1990
- 2-for-1Stock splitJun 2, 1986
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02Officer / director changeNov 16, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsOct 21, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsOct 21, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsAug 20, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 16, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.03, 5.07, 9.01Officer / director change · Bylaw amendment · Shareholder voteApr 27, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsApr 17, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsApr 16, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMar 23, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationMar 9, 2026
EDGAR ↗
About ABBOTT LABORATORIES
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersABBOTT PARK, IL
IncorporatedIL
SEC CIK0000001800 ↗











